Gurnet Point Capital and Patient Square Capital Acquire Radius Health

Paratek Pharmaceuticals Completes Combination with Radius Health

March 20, 2026

Pharmaceuticals

Paratek Pharmaceuticals completed its combination with Radius Health, adding Radius’s osteoporosis therapy TYMLOS (abaloparatide) to Paratek’s specialty pharmaceutical portfolio. The combined company is expected to generate nearly $1 billion in revenue in 2026 and expands the platform across multiple high-need therapeutic areas.

Patient Square Capital to Acquire Paradigm

February 12, 2026

Healthcare Services

Paradigm, a specialty care management organization focused on complex injuries and diagnoses, has entered into a definitive agreement to be acquired by Patient Square Capital. The transaction is expected to close in the first half of 2026, marking the conclusion of Paradigm’s partnership with OMERS Private Equity.

B-FLEXION Life Sciences to Acquire Remaining 57% of Radius Health from Patient Square and Webster Equity Partners

January 12, 2026

Pharmaceuticals

B-FLEXION Life Sciences has agreed to purchase the remaining 57% interest in Radius Health held by affiliates of Patient Square Capital and Webster Equity Partners. Radius, a specialty biopharmaceutical focused on bone health, had been taken private by B-FLEXION and Patient Square in August 2022. The transaction is expected to close by the end of Q1 2026.

Patient Square Capital Makes Strategic Investment in CorroHealth; Carlyle to Share Joint Control

October 24, 2024

Healthcare Services

CorroHealth, a Plano-based provider of clinically led revenue cycle management (RCM) and healthcare analytics, has signed definitive agreements for a strategic investment from Patient Square Capital. Current shareholders including Carlyle will remain investors, and Patient Square and Carlyle will share joint control as CorroHealth pursues further organic and inorganic growth.

Gurnet Point Capital and Novo Holdings Acquire Paratek Pharmaceuticals

September 21, 2023

Pharmaceuticals

Gurnet Point Capital and Novo Holdings completed the acquisition of Paratek Pharmaceuticals for $2.15 per share in cash plus a $0.85 CVR tied to NUZYRA sales, in a transaction valued at approximately $462 million including assumed debt. Oaktree provided $175 million of debt financing; following closing Paratek will be taken private and delisted from Nasdaq as the buyers aim to accelerate commercialization of NUZYRA and expand Paratek's anti-infective portfolio.

Elliott, Patient Square and Veritas Acquire Syneos Health for ~$7.1B

May 10, 2023

Healthcare Services

A consortium of private investment firms—Elliott Investment Management, Patient Square Capital and Veritas Capital—has completed the acquisition of Syneos Health for $43.00 per share, a transaction valued at approximately $7.1 billion including debt. Syneos Health will become a privately held company, with the new owners planning to accelerate its transformation, invest in technology and strengthen its integrated biopharmaceutical services.